Please assess the completion status of the following clinical trial:

Trial Title: Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be able to understand, in the opinion of the investigator, the informed consent form.~* be diagnosed with schizophrenia~* report dissatisfaction with current medication~* have an aspect of schizophrenia management which could potentially benefit from a change in antipsychotic medication~* receive risperidone 4 mg or 6 mg for at least 4 weeks before the start of the study.~Exclusion Criteria:~* Unable to swallow study drug whole with the aid of water~* cannot have received an investigational drug, used an investigational medical device, or participated in a clinical study that altered their medication within 6 months before the first administration of study drug, or have participated in more than 2 investigational drug studies within the past 12 months~* no other major mental health diagnosis except for tobacco dependance~* no use of cocaine or heroin within 3 months before the first administration~* no history of treatment with any antipsychotic in addition to treatment with risperidone, or treatment with paliperidone, within 30 days before the baseline visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks
- 001 (Type: EXPERIMENTAL): Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).